Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 275–286 | Cite as

New developments in the pharmacotherapy of inflammatory bowel disease

  • J. W. Harting
Drugs in the Pipeline


In this article the clinical features and aetiology of inflammatory bowel diseases are described and current pharmacotherapeutic possibilities are explored. Also reviewed are recent developments and future prospects for the pharmacotherapy of inflammatory bowel diseases, including aminosalicylates, corticosteroids, immunosuppressants, lipoxygenase inhibitors, fish oil, sucralfate, bismuth compounds, free radical scavengers, (hydroxy)chloroquine, sodium cromoglycate and methotrexate.


Crohn's disease Inflammatory bowel disease Ulcerative colitis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991;100:1638–43.PubMedGoogle Scholar
  2. 2.
    Tytgat GNJ, De Groote J, Van Tongeren JHM, Vantrappen G. eds. Leerboek maag-, darm- en leverziekten. Utrecht: Bohn Scheltema & Holkema, 1985:198–223.Google Scholar
  3. 3.
    Fretland DJ, Djuric SW, Gaginella TS. Eicosanoids and inflammatory bowel disease: regulation and prospects for therapy. Prostaglandins Leukot Essent Fatty Acids 1990;41:215–33.PubMedGoogle Scholar
  4. 4.
    Sottile RF, Quandt CM, Present DH, Mehl B. Medical management of inflammatory bowel disease. DICP 1989;23:963–73.PubMedGoogle Scholar
  5. 5.
    Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease: a review of their mechanisms of efficacy and place in therapy. Drugs 1989;38(2):267–88.PubMedGoogle Scholar
  6. 6.
    Hampson SJ, McFadden JJ, Hermon-Taylor J. Mycobacteria and Crohn's disease. Gut 1988;29:1017–19.PubMedGoogle Scholar
  7. 7.
    Seldenrijk CA, Drexhage HA, Meuwissen SGM, Meijer CJLM. T-cellular immune reactions (in macrophage inhibition factor assay) againstMycobacterium paratubereulosis, Mycobacterium kansasii, Mycobacterium tuberculosis, Mycobacterium, avium in patients with inflammatory bowel disease. Gut 1990;31:529–35.PubMedGoogle Scholar
  8. 8.
    Sullivan SN. Hypothesis revisited: toothpaste and the cause of Crohn's disease. Lancet 1990;336:1096–7.PubMedGoogle Scholar
  9. 9.
    Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason J. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991;101:84–9.PubMedGoogle Scholar
  10. 10.
    North CS, Alpers DH, Helzer JE, Spitznagel EL, Clouse RE. Do life events or depression exacerbate inflammatory bowel disease? Ann Intern Med 1991;114: 381–6.PubMedGoogle Scholar
  11. 11.
    Jewell DP. Aetiology and pathogenesis of ulcerative colitis and Crohn's disease. Postgrad Med J 1989;65:718–9.PubMedGoogle Scholar
  12. 12.
    Tobin MV, Logan RFA, Langman MJS, McConnell RB, Gilmore JT. Cigarette smoking and inflammatory bowel disease. Gastroenterology 1987;93:316–21.PubMedGoogle Scholar
  13. 13.
    Cope GF, Heatley RV, Kelleher J. Smoking and colonic mucus in ulcerative colitis. BMJ 1986;293:481.Google Scholar
  14. 14.
    Kim YS, Byrd JC. Ulcerative colitis: a specific mucin defect? Gastroenterology 1984;87:1193–5.Google Scholar
  15. 15.
    Froese DP, Haggitt RC, Friend WG. Ulcerative colitis in the autotransplanted neovagina. Gastroenterology 1991;100:1749–52.PubMedGoogle Scholar
  16. 16.
    Wakefield AJ, Dhillon AP, Rowles PM, Sawyerr AM, Pittilo RM, Lewis AAM, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;1057–62.Google Scholar
  17. 17.
    Sawyerr AM, Wakefield AJ, Hudson M, Dhillon AP, Pounder RE. Review article: the pharmacological implications of leucocyte-endothelial cell interactions in Crohn's disease. Aliment Pharmacol Ther 1991;5:1–14.Google Scholar
  18. 18.
    Karting JW. Leukotrienes. Pharm Weekblad 1990; 125:9–17.Google Scholar
  19. 19.
    Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86:453–60.PubMedGoogle Scholar
  20. 20.
    Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut 1987;28:1002–7.PubMedGoogle Scholar
  21. 21.
    Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J.In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis andClostridium difficile colitis. Gastroenterology 1988;95:11–7.PubMedGoogle Scholar
  22. 22.
    Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989;96:29–36.Google Scholar
  23. 23.
    Wallace JL. 5-Lipoxygenase: a rational target for therapy of inflammatory bowel disease? TiPS 1990;11:51–3.PubMedGoogle Scholar
  24. 24.
    Verspaget HW, Pena AS, Weterman IT, Lamers CBHW. Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content. Gut 1988;29:223–8.PubMedGoogle Scholar
  25. 25.
    Parks DA. Oxygen radicals: mediators of gastrointestinal pathophysiology. Gut 1989;30:293–8.PubMedGoogle Scholar
  26. 26.
    Hanauer SB. 5-ASA enema therapy. Neth J Med 1989;35:S11–20.PubMedGoogle Scholar
  27. 27.
    Stolk LML, Wiltink EH. Mesalazine (Asacol®, Pentasa®, Salofalk®) and olsalazine (Dipentum®). Pharm Weekbl 1989;124:462–7.Google Scholar
  28. 28.
    Hanauer SB. Aminosalicylates: old and new. Mount Sinai J Med 1989;57:283–7.Google Scholar
  29. 29.
    Christensen LA, Fallingborg J, Abildgaard K, Jacobsen BA, Sanchez G, Hansen SH, et al. Topical and systemic availibility of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990;4:523–33.PubMedGoogle Scholar
  30. 30.
    Verzijl JM, Van Dijk A. Orientation of oral mesalasine preparations in colitis ulcerosa and Crohn's disease. Pharm Weekbl 1991;126:232–8.Google Scholar
  31. 31.
    Stolk LML, Rietbroek R, Wiltink EH, Tukker JJ. Dissolution profiles of mesalazine formulationsin vitro. Pharm Weekbl [Sci] 1990;12:200–4.Google Scholar
  32. 32.
    Jansen TLTA. Long-term treatment with mesalasine enema's in colitis ulcerosa. Ned Tijdschr Geneeskd 1991;135:1367.Google Scholar
  33. 33.
    D'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 1990;33:394–7.PubMedGoogle Scholar
  34. 34.
    Anonymous. Updated evaluation: olsalazine. Hosp Pharm 1991;26:445–8.Google Scholar
  35. 35.
    Wadworth AN, Fitton A. Olsalazine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in inflammatory bowel disease. Drugs 1991;41:647–64.PubMedGoogle Scholar
  36. 36.
    Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347–51.PubMedGoogle Scholar
  37. 37.
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterology 1990;85:717–21.Google Scholar
  38. 38.
    Love MA, Rubin PH, Chapman ML, Present DH. 6-Mercaptopurine is effective in intractable proctosigmoiditis. AGA abstracts. Gastroenterology 1991;100(5):A832.Google Scholar
  39. 39.
    Hawthorne AB, Logan RFA, Hawkey CJ, Foster PN, Swarbrick ET, Scott BB, et al. Efficacy of azathioprine in maintaining remission in ulcerative colitis: a placebo-controlled withdrawal trial. AGA abstracts. Gastroenterology 1991;100(5):A216.Google Scholar
  40. 40.
    Steinhart AH, Baker JP, Brzezinksky A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterology 1990;12:271–5.Google Scholar
  41. 41.
    O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101:39–46.PubMedGoogle Scholar
  42. 42.
    Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1989;18(1):57–71.PubMedGoogle Scholar
  43. 43.
    Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123–9.PubMedGoogle Scholar
  44. 44.
    Gradon JD, Zimbalist EH. Is trimethoprim-sulfamethoxazole helpful in Crohn's disease? J Clin Gastroenterology 1990;12:270–1.Google Scholar
  45. 45.
    Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety 1991;6(3):192–219.PubMedGoogle Scholar
  46. 46.
    Ruderman WB. Newer pharmacologic agents for the therapy of inflammatory bowel disease. Med Clin North Am 1990;74:133–53.PubMedGoogle Scholar
  47. 47.
    Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990;74:119–31.PubMedGoogle Scholar
  48. 48.
    Hanauer SB. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol 1990;25 Suppl 175:97–106.PubMedGoogle Scholar
  49. 49.
    Dew MJ. Medical treatment of inflammatory bowel disease. Curr Opin Gastroenterol 1988;4:472–8.Google Scholar
  50. 50.
    Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal disease (part II). Clin Pharmacokinet 1990;19(2):94–125.PubMedGoogle Scholar
  51. 51.
    Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 1990;112:50–60.PubMedGoogle Scholar
  52. 52.
    Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4(7):407–14.Google Scholar
  53. 53.
    Mulder CJJ, Rondas AALM, Wiltink EH, Tytgat GNJ. Topical corticosteroids in inflammatory bowel disease. Neth J Med 1989;35:S27–34.PubMedGoogle Scholar
  54. 54.
    Mulder CJJ, Kneppelhout J-C, Schipper DL. Progress in the steroid therapy of ileocolitis. In: eds? Topics in gastroenterology. Dordrecht: Kluwer Academic Press. In press.Google Scholar
  55. 55.
    Halpern Z, Sold O, Baratz M, Konikoff F, Halak A. A controlled trial of beclomethasone versus betamethasone enemas in distal ulcerative colitis. J Clin Gastroenterol 1991;13:38–41.PubMedGoogle Scholar
  56. 56.
    Carpani de Kaski M, Peters AM, Lavender JP, Hodgson HJF. Fluticasone propionate in Crohn's disease. Gut 1991;32:657–61.PubMedGoogle Scholar
  57. 57.
    Danielsson A, Hellers G, Lyrenas E, Löfberg R, Nilsson A, Olsson O, et al. A controlled randomised trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987;22:987–92.PubMedGoogle Scholar
  58. 58.
    Lamers C, Meijer J, Engels L, Bos L, Van Hogezand R, Driessen W, et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of procititis and proctosigmoiditis. AGA Abstracts. Gastroenterology 1991;100(5):A223Google Scholar
  59. 59.
    Tarpila S, Turunen U, Seppala K, Aukee S, Pikkarainen P, Elomaa I, et al. Budesonide enema is as effective as hydrocortisone foam in proctitis. Scand J Gastroenterol 1991;26 Suppl 1:83:81.Google Scholar
  60. 60.
    Löfberg R, Danielsson A, Salde L. Oral budesonide in active ileocecal Crohn's disease: a pilot trial with a topical acting steroid. AGA Abstracts. Gastroenterology 1991;100(5):A226.Google Scholar
  61. 61.
    Wolman SL, Greenberg GR. Oral budesonide in active Crohn's disease: an initial experience. AGA Abstracts. Gastroenterology 1991;100(5):A263.Google Scholar
  62. 62.
    Brynskov J, Freund L, Nörby Rasmussen S, Lauritsen K, et al. A placebo-controlled, double-blind, randomised trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845–50.PubMedGoogle Scholar
  63. 63.
    Brynskov J, Freund L, Nörby Rasmussen S, Lauritsen K, et al. Final report on a placebo-controlled, doubleblind, randomised, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991;26:689–95.PubMedGoogle Scholar
  64. 64.
    Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990;336:16–9.PubMedGoogle Scholar
  65. 65.
    Summers JB. Inhibitors of leukotriene biosynthesis. Drug News Perspect 1990;3(9):517–26.Google Scholar
  66. 66.
    Staerk Laursen L, Naesdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990;335:683–5.PubMedGoogle Scholar
  67. 67.
    Laursen LS, Lauritsen K, Rask-Madsen J, Jacobsen O, et al. Abbott-64077, a potent lipoxygenase inhibitor in the treatment of ulcerative colitis. Abstract. World Congresses of Gastroenterology, Digestive Endoscopy and Colo-proctology, Sydney, Australia, 1990.Google Scholar
  68. 68.
    Collawn C, Rubin P, Perez N, Reyes E, et al. Experimental use of a 5-lipoxygenase inhibitor (Abbott-64077) in human ulcerative colitis. Abstract, American College of Gastroenterology, New Orleans, 1989.Google Scholar
  69. 69.
    Carter GW, Young PR, Albert DH, Bouska JB, et al. A-64077, a new potent orally active 5-lipoxygenase inhibitor. In: Zor U, Naor Z, Danon A, eds. Leukotrienes and prostanoids in health and disease. New trends in lipid mediators research. Basel: Karger, 1989:50–5.Google Scholar
  70. 70.
    Carter GW, Young PR, Albert DH, Bouska J. 5-Lipoxygenase inhibitory activity of Zileuton. J Pharmacol Exp Ther 1991;256(3):929–37.PubMedGoogle Scholar
  71. 71.
    Carter GW, Young PR, ALbert D, Bouska J, et al. Development of A-64077, a promising agent for the treatment of leukotriene-mediated diseases. Abstract. 7th International Conference on Prostaglandins and Related Compounds, Florence, 1990.Google Scholar
  72. 72.
    Dube LM. Clinical pharmacology/pharmacokinetics of Zileuton, a 5-lipoxygenase inhibitor. Abstract. 4th Interscience World Conference on Inflammation Anti-rheumatics, Analgesics, Immunomodulators, Geneva, 1991.Google Scholar
  73. 73.
    Pajares JM. Does dietary fish oil maintain the remission of Crohn's disease (CD): a study case control. AGA Abstracts. Gastroenterology 1991;100(5):A228.Google Scholar
  74. 74.
    Srivastava ED, Swift GL, Wilkinson S, Williams GT, Evans BK, Rhodes J. Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis. Aliment Pharmacol Ther 1990;4:577–81.PubMedGoogle Scholar
  75. 75.
    Ryder SD, Walker RJ, Jones H, Rhodes JM. Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Ther 1990;4:333–8.PubMedGoogle Scholar
  76. 76.
    Nolte H, Spjeldnaes N, Kruse A, Windelborg B. Histamine release from gut mast cells from patients with inflammatory bowel diseases. Gut 1990;31:791–4.PubMedGoogle Scholar
  77. 77.
    Grace RH, Gent AE, Hellier MD. Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis. Gut 1987;28:88–92.PubMedGoogle Scholar
  78. 78.
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353–6.PubMedGoogle Scholar
  79. 79.
    Kozarek RA, Patterson DJ, Botoman VA, Ball TJ, Gelfand MD. Methotrexate use in inflammatory bowel disease patients who failed azathioprine or 6-mercaptopurine. AGA Abstracts. Gastroenterology 1991;100(5):A222.Google Scholar
  80. 80.
    Björck S, Dahlström A, Ahlman H. Topical treatment with lidocaine in patients with ulcerative colitis. AGA Abstracts. Gastroenterology 1991;100(5):A194.Google Scholar
  81. 81.
    Asakura H, Sasagawa T, Takizawa H, Bannai H, Yamaguchi M, Narisawa R. Clinical effectiveness and immunological changes in ulcerative colitis by massive immunoglobulin G treatment. AGA Abstracts. Gastroenterology 1991;100(5):A194.Google Scholar
  82. 82.
    Gaffney PR, O'Leary JJ, Doyle CT, Gaffney A, Hogan J, et al. Response to heparin in patients with ulcerative colitis. Lancet 1991;337:238–9.PubMedGoogle Scholar
  83. 83.
    Srivastava ED, Russell MAH, Masterton JG, Rhodes J. Transdermal nicotine in ulcerative colitis. Gastroenterology 1991;100(5):A252.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • J. W. Harting
    • 1
  1. 1.Oosterschelde Hospital FoundationGoesthe Netherlands

Personalised recommendations